Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2579-2590

  Advani, Sunil J ^a   Buckel, Lisa ^c   Chen, Nanhai G ^a,b   Scanderbeg, Daniel J ^a   Geissinger, Ulrike ^b   Zhang, Qian ^a,b   Yu, Yong A ^a,b   Aguilar, Richard J ^b   Mundt, Arno J ^a   Szalay, Aladar A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSIMETRY; DRUG EFFICACY; GLIOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR VIRUS; TUMOR XENOGRAFT; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; BRAIN NEOPLASMS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; FIBROBLASTS; GLIOMA; KIDNEY; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; RADIATION, IONIZING; SURVIVAL RATE; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860511601     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2394     Document Type: Article

References (28)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 2009;6:558-69.
3. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50. (Pubitemid 37328895)
4. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74. (Pubitemid 30303584)
5. Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003;65:203-26. (Pubitemid 37526814)
6. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 2010;21:103-17.
7. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006;66:637-46. (Pubitemid 44436713)
8. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010;18: 251-63.
9. Kanai R, Wakimoto H,Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol 2010;6:619-34.
10. Gridley DS, Andres ML, Li J, Timiryasova T, Chen B, Fodor I. Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol 1998;13:1093-8. (Pubitemid 28506083)
11. Timiryasova TM, Gridley DS, Chen B, Andres ML, Dutta-Roy R, Miller G, et al. Radiation enhances the anti-tumor effects of vaccinia- p53 gene therapy in glioma. Technol Cancer Res Treat 2003;2:223-35. (Pubitemid 37121886)
12. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a newparadigm for destruction of therapeutically intractable tumors. Gene Ther 1998;5:160-5. (Pubitemid 28077742)
13. Bradley JD, Kataoka Y, Advani SJ, Chung SM, Arani RB, Gillespie GY, et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999;5:1517-22. (Pubitemid 29282961)
14. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007;13:7155-65. (Pubitemid 350276902)
15. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008;14:912-23. (Pubitemid 351231176)
16. Adusumilli PS, Stiles BM, Chan MK, Chou TC, Wong RJ, Rusch VW, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg 2005;80:409-16; discussion 416-7.
17. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P, et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005;12:715-22. (Pubitemid 41045570)
18. Veerapong J, Bickenbach KA, Shao MY, Smith KD, Posner MC, Roizman B, et al. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 2007;67: 8301-6. (Pubitemid 47395168)
19. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007;67: 429-32. (Pubitemid 46192175)
20. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71.
21. Chen NG, Szalay AA. Oncolytic vaccinia virus: a theranostic agent for cancer. Future Virol 2010;5:21.
22. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7. (Pubitemid 34013887)
23. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007;67:10038-46. (Pubitemid 47621255)
24. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004;22:313-20. (Pubitemid 38295764)
25. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102.
26. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A 2009;106:12915-20.
27. Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009;15: 2777-88.
28. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 2009;8:141-51.